GLAXO — GlaxoSmithKline Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹318.73bn
- IN₹301.73bn
- IN₹32.52bn
- 96
- 11
- 91
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 41.53 | ||
| PEG Ratio (f) | 3.64 | ||
| EPS Growth (f) | 12.9% | ||
| Dividend Yield (f) | 1.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.7 | ||
| Price to Tang. Book | 21.1 | ||
| Price to Free Cashflow | 49.42 | ||
| Price to Sales | 9.63 | ||
| EV to EBITDA | 44.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 34.11% | ||
| Return on Equity | 35.33% | ||
| Operating Margin | 18.63% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 31,281.19 | 32,243.81 | 29,256.02 | 32,780.29 | 32,517.23 | 33,648.5 | 36,493 | 2.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.95 | -22.35 | +19.95 | -5.44 | +62.24 | +11.74 | +12.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.
Directors
- Deepak Parekh NEC (77)
- Puja Thakur CFO
- D. Bartaria EVP
- H. Buch EVP
- Ajay Nadkarni CCO
- S. Khanna VFN
- S. Dheri VPR
- K. Hazari VPR
- Annaswamy Vaidheesh VPR
- Sridhar Venkatesh MDR
- V. Desai GMG
- Andrew Aristidou EDR
- Mark Dawson NED
- Subesh Williams NED
- Pradeep Bhide NID (70)
- Nihal Kaviratne NID (77)
- Anami Roy NID (67)
- D. Sundaram NID (61)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 13th, 1924
- Public Since
- November 3rd, 1994
- No. of Shareholders
- 124,912
- No. of Employees
- 3,680
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 169,410,000
- Address
- Dr Annie Besant Road, Worli, MUMBAI, 400030
- Web
- https://india-pharma.gsk.com/en-in/
- Phone
- +91 2224959595
- Contact
- Ajay Nadkarni
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for GLAXO
GlaxoSmithKline Pharmaceuticals Ltd Annual Shareholders Meeting
Q1 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Release
Similar to GLAXO
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the GlaxoSmithKline Pharmaceuticals share price?
As of Today at 19:09 UTC, shares in GlaxoSmithKline Pharmaceuticals are trading at IN₹1,881.40. This share price information is delayed by 15 minutes.
How has the GlaxoSmithKline Pharmaceuticals share price performed this year?
Shares in GlaxoSmithKline Pharmaceuticals last closed at IN₹1,881.40 and the price had moved by +49.58% over the past 365 days. In terms of relative price strength the GlaxoSmithKline Pharmaceuticals share price has outperformed the S&P BSE 100 Index by +13.37% over the past year.
What are the analyst and broker recommendations for GlaxoSmithKline Pharmaceuticals?
The overall consensus recommendation for GlaxoSmithKline Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the GlaxoSmithKline Pharmaceuticals dividend yield?
The GlaxoSmithKline Pharmaceuticals dividend yield is 1.7% based on the trailing twelve month period.
Does GlaxoSmithKline Pharmaceuticals pay a dividend?
Last year, GlaxoSmithKline Pharmaceuticals paid a total dividend of IN₹32.00, and it currently has a trailing dividend yield of 1.7%. We do not have any data on when GlaxoSmithKline Pharmaceuticals is to next pay dividends.
When does GlaxoSmithKline Pharmaceuticals next pay dividends?
We do not have data on when GlaxoSmithKline Pharmaceuticals is to next pay dividends. The historic dividend yield on GlaxoSmithKline Pharmaceuticals shares is currently 1.7%.
How do I buy GlaxoSmithKline Pharmaceuticals shares?
To buy shares in GlaxoSmithKline Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GlaxoSmithKline Pharmaceuticals?
As of the previous close price of IN₹1,881.40, shares in GlaxoSmithKline Pharmaceuticals had a market capitalisation of IN₹318.73bn.
Where are GlaxoSmithKline Pharmaceuticals shares listed?
Here are the trading details for GlaxoSmithKline Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GLAXO
What kind of share is GlaxoSmithKline Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum GlaxoSmithKline Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GlaxoSmithKline Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in GlaxoSmithKline Pharmaceuticals is IN₹2,011.00. That is 6.89% above the last closing price of IN₹1,881.40.
Analysts covering GlaxoSmithKline Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹40.13 for the next financial year.
What is the trend in the GlaxoSmithKline Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlaxoSmithKline Pharmaceuticals. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +4.52%.
As of the last closing price of IN₹1,881.40, shares in GlaxoSmithKline Pharmaceuticals were trading +8.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GlaxoSmithKline Pharmaceuticals PE Ratio?
The GlaxoSmithKline Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 41.53. The shares last closed at IN₹1,881.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GlaxoSmithKline Pharmaceuticals?
GlaxoSmithKline Pharmaceuticals' management team is headed by:
- Deepak Parekh - NEC
- Puja Thakur - CFO
- D. Bartaria - EVP
- H. Buch - EVP
- Ajay Nadkarni - CCO
- S. Khanna - VFN
- S. Dheri - VPR
- K. Hazari - VPR
- Annaswamy Vaidheesh - VPR
- Sridhar Venkatesh - MDR
- V. Desai - GMG
- Andrew Aristidou - EDR
- Mark Dawson - NED
- Subesh Williams - NED
- Pradeep Bhide - NID
- Nihal Kaviratne - NID
- Anami Roy - NID
- D. Sundaram - NID